CHF Solutions Names David B. Springer President and Chief Operating Officer; Executive to Focus on Building Sales for Innovative Heart Failure Treatment.BROOKLYN PARK Brooklyn Park, city (1990 pop. 56,381), Hennepin co., SE Minn., a suburb of Minneapolis; chartered as a city 1969. Manufacturing includes machinery, wood and metal products, tools, feeders, and medical and pharmaceutical supplies. , Minn. -- CHF CHF In currencies, this is the abbreviation for the Swiss Franc. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. Solutions, Inc., has named David B. Springer president and chief operating officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. , effective immediately. Springer will be responsible for the global leadership of CHF Solutions' sales, marketing, R&D and operations staff. He plans to leverage the company's landmark clinical trial results to expand sales and marketing efforts for the Aquadex FlexFlow(TM), the company's innovative system used to treat fluid overload fluid overload Hypervolemia, plethora Medtalk A systemic excess of fluids. Cf Volume depletion. in heart failure patients. "I am very excited to have Dave join our executive leadership team," said John Erb, chief executive officer of CHF Solutions. "Dave brings great strengths to CHF Solutions. We will benefit immensely from his experience commercializing new technologies, his proven record of success and his passion." Most recently, Springer served as senior vice president of the U.S. Division of St. Jude Medical St. Jude Medical, Inc. NYSE: STJ is a $2.9 billion global cardiovascular device company, with headquarters in St. Paul, Minnesota, United States. The company sells products in more than 100 countries and has over 20 operations and manufacturing facilities worldwide. , where he drove the domestic strategy and operational plan, as well as had primary brand management accountability. From 2000 to 2002, Springer was the chief operating officer at AndyDevice (acquired by Hiddenmind Technology), a turnaround where he successfully realigned the business focus toward ambitious growth. Previously, he held the positions of executive vice president of business development and senior vice president of sales at WebMD, where he played a critical role on the founding management team, transforming and building a start-up medical device and telemedicine company into the nation's leading Internet healthcare business. Earlier, he held various leadership, sales and marketing roles at Intermedics, Kimberly Clark Healthcare and Procter & Gamble. "On the heels of the very positive UNLOAD study results announced at the American College of Cardiology The American College of Cardiology (ACC) is a nonprofit medical association established in 1949 to educate, research and influence health care public policy. The president for the 2006–2007 year is Steven E. Nissen. [1] The organization has 39 chapters in the U.S. conference, this company has all the right pieces in place for great commercial success," said Springer. "We believe that the significant clinical benefits for patients with fluid overload shown by UNLOAD can translate into economic benefits for hospitals and health plans." Springer graduated from Purdue University Purdue University (pərdy  `, -d`), main campus at West Lafayette, Ind. in 1986 with a bachelor's degree in industrial management and a minor in industrial engineering. About the UNLOAD study UNLOAD is a randomized ran·dom·ize tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es To make random in arrangement, especially in order to control the variables in an experiment. , multicenter study of 200 patients involving 28 hospitals and medical centers across the U.S. that details the immediate and long-term benefits for heart failure patients receiving Aquapheresis(TM) therapy to treat fluid overload. It is the first randomized clinical study of its type to compare the safety and efficacy of treatment with the Aquadex FlexFlow system, a non-drug-based option, with standard intravenous diuretic drug therapy to treat fluid overload in heart failure patients. Its landmark results were first presented at the 2006 American College of Cardiology conference in March. For more information about the UNLOAD study, go to http://www.chfsolutions.com/unload_lbct.html. About Fluid Overload and Heart Failure Fluid overload can be caused by many things, including problems with the heart, kidneys, lungs or any combination of these vital organs. The leading cause of fluid overload is congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. (CHF), sometimes referred to as heart failure (HF). Heart failure is a condition that affects approximately 5 million Americans and is responsible for one million hospitalizations annually. More than 500,000 new cases of heart failure are diagnosed each year. The estimated economic burden of heart failure care exceeds $28 billion annually in the United States. Due to prolonged hospitalizations and high readmission readmission Managed care The admission of a Pt to a health care facility for a condition–eg, stroke, MI, GI bleeding, hip fracture, cancer surgery, shortly after discharge. See nth admission. Cf Admission, Discharge. rates, many hospitals often lose more than $1,000 for each heart failure patient admitted. About Aquapheresis, the Aquadex FlexFlow and CHF Solutions CHF Solutions' Aquapheresis therapy with the Aquadex FlexFlow system allows physicians to remove the excess salt and water in patients with fluid overload where, when and how they want. Inpatient or outpatient, peripheral or central venous access Venous Access Definition Venous access introduces a needle into a vein, usually for the purpose of withdrawing blood or administering medication. , its low blood flow, low extracorporeal extracorporeal /ex·tra·cor·po·re·al/ (-kor-por´e-al) situated or occurring outside the body. ex·tra·cor·po·re·al adj. Situated or occurring outside the body. blood volume, and precise removal rates enable dependable fluid removal. CHF Solutions, based in Brooklyn Park, Minn., is a privately held manufacturer of medical devices for cardiac care. The company's mission is to provide medical practitioners with innovative and practical solutions that enable the treatment of patients with unmet clinical needs. For more information, go to www.chfsolutions.com. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion